옵션 체인은 다양한 행사가격과 만기일에 대한 Personalis의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Personalis에 대한 시장 심리를 평가합니다..

Personalis (NASDAQ:PSNL) 주식, 옵션 체인

PERSONALIS INC

Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Cathie Wood's Buys The Dip In Tempus AI, Coinbase But Sells Ark's Bitcoin ETF Shares Amid Crypto Meltdown

Equities

News

Markets

Tech

ETFs

ABSI

ARKF

ARKK

ARKQ

ARKW

IBTA

PATH

PSNL

RBLX

ROKU

RXRX

금요일, 캐시 우드가 이끄는 아크 인베스트가 몇 가지 주요 거래를 진행했다. 이 거래는 로블록스(NYSE:RBLX), 로쿠(NASDAQ:ROKU), 유아이패스(NYSE:PATH), 아이보타(NYSE:IBTA), 퍼스널리스(NGM:PSNL), 앱시(NASDAQ:ABSI) 그리고 리커전 파마슈티컬스(NASDAQ:RXRX)와 같은 주식들에 대한 활동이 두드러졌다.

캐시 우드의 아크 인베스트가 시장 하락에 로블록스, 로쿠 및 유아이패스 매도

Headquarters_Rahway-Site-Entrance_HI

Technicals

Trading Ideas

HNSPF

머크 앤드 컴퍼니(NYSE:MRK)의 주가가 목요일에 소폭 반등세를 보이고 있지만 여전히 약세에서 벗어나지 못한 형국이다. 주가가 결국 95.00달러 정도 수준에 도달하면 주가가 반전되어 상승할 가능성이 높다. 차트에서 볼 수 있듯이 이는 11월 말에 일어난 일이다. 이러한 이유로 우리 기술 분석 팀은 이를 오늘의 주식으로 선정했다.

오늘의 주식: 머크의 하락 추세는 어디에서 끝나나?

Cathie Wood

Specialty ETFs

BLDE

DKNG

TSLA

테슬라(NASDAQ:TSLA)의 주가는 잠재적으로 암울한 분기에 대한 우려와 제품 파이프라인 계획의 전략적 변화에 대한 소문으로 인해 화요일 3일 연속 하락 마감했다. 이러한 곤경에도 불구하고 테슬라 강세를 주장하는 캐시 우드(Cathie Wood)가 운영하는 아크 인베스트(Ark Invest)는 이 주식을 매수했다.

캐시 우드의 아크는 테슬라가 3일 연속 하락하는 동안 330만 달러의 주식 매수

Personalis Inc

<h3>Gainers</h3>
<ul>
<li>Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) shares moved upwards by 8.3% to $1.31 during Tuesday's after-market session. The company's market cap stands at $29.9 million. </li>
<li>Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) shares moved upwards by 6.34% to $18.1. The market value of their outstanding shares is at $930.8 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>XWELL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) stock rose 5.8% to $0.97. The market value of their outstanding shares is at $5.1 million. As per the news, the Q1 earnings report came out today. </li>
<li>Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) shares moved upwards by 5.63% to $110.4. The company's market cap stands at $11.0 billion. The company's, Q2 earnings came out today. </li>
<li>Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) shares moved upwards by 4.98% to $0.39. The company's market cap stands at $16.7 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) shares rose 4.81% to $6.75. The market value of their outstanding shares is at $1.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Neo-Concept International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) shares fell 17.6% to $0.35 during Tuesday's after-market session. The company's market cap stands at $7.1 million. </li>
<li>Outdoor Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) shares fell 12.16% to $1.59. The market value of their outstanding shares is at $188.8 million. </li>
<li>Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares decreased by 10.26% to $33.0. The company's market cap stands at $1.2 billion. </li>
<li>Mingteng International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) shares fell 9.23% to $12.3. The market value of their outstanding shares is at $84.1 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) stock declined by 8.47% to $1.19. The company's market cap stands at $9.4 million. As per the news, the FY earnings report came out today. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) stock fell 5.31% to $0.4. The company's market cap stands at $2.7 million. As per the press release, Q1 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AYRO

BGFV

LVLU

MTEN

POWW

SDHC

SHCO

XWEL

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 39.5% to $0.38 during Tuesday's after-market session. The company's market cap stands at $55.3 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock rose 26.37% to $0.16. The company's, Q1 earnings came out 3 days ago. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock rose 15.6% to $0.81. The market value of their outstanding shares is at $8.2 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock rose 9.8% to $5.61. The market value of their outstanding shares is at $510.8 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock rose 7.23% to $0.44. The market value of their outstanding shares is at $12.1 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock increased by 6.7% to $0.52. The market value of their outstanding shares is at $53.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 9.0% to $5.49 during Tuesday's after-market session. The market value of their outstanding shares is at $83.5 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares declined by 6.46% to $4.2. The company's market cap stands at $4.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 6.21% to $11.18. The company's market cap stands at $206.7 million. </li>
<li>HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) stock declined by 5.95% to $1.9. The company's market cap stands at $95.1 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 5.94% to $0.39. The company's market cap stands at $7.1 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock decreased by 5.77% to $0.66. The market value of their outstanding shares is at $92.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

HLVX

HSCS

INTS

MTVA

ONMD

OPRX

PTPI

VNRX

XTNT

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock moved upwards by 8.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $21.9 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock moved upwards by 6.58% to $0.42. The market value of their outstanding shares is at $5.2 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares rose 6.28% to $0.33. The company's market cap stands at $8.0 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) shares rose 5.73% to $3.22. The market value of their outstanding shares is at $109.8 million. </li>
<li>Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) shares rose 4.93% to $2.55. The company's market cap stands at $127.6 million. The company's, Q1 earnings came out today. </li>
<li>GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) stock rose 4.8% to $1.09. The company's market cap stands at $281.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centuri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) stock fell 8.6% to $17.92 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) stock fell 7.33% to $0.82. The market value of their outstanding shares is at $2.5 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>FBS Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBGL#NASDAQ">FBGL</a>) shares fell 7.0% to $0.65. The market value of their outstanding shares is at $8.7 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) stock decreased by 6.78% to $0.16. The company's market cap stands at $22.8 million. </li>
<li>Lakeside Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSH#NASDAQ">LSH</a>) stock declined by 5.95% to $0.95. The market value of their outstanding shares is at $7.1 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Samfine Creation Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) stock fell 5.01% to $0.87. The company's market cap stands at $17.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRGO

CTRI

DXST

FBGL

NEOV

PSIG

SFHG

UGRO

XPON

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) stock moved upwards by 9.5% to $1.38 during Tuesday's after-market session. The market value of their outstanding shares is at $15.7 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>PicoCELA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) stock increased by 8.78% to $0.52. The market value of their outstanding shares is at $16.0 million. </li>
<li>Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) stock increased by 6.49% to $5.9. The market value of their outstanding shares is at $964.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) shares moved upwards by 5.38% to $0.47. The company's market cap stands at $67.9 million. </li>
<li>Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) stock increased by 5.2% to $171.27. The market value of their outstanding shares is at $29.5 billion. The company's, Q2 earnings came out today. </li>
<li>Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) shares increased by 5.0% to $1.26. The company's market cap stands at $299.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares fell 46.0% to $1.69 during Tuesday's after-market session. The company's market cap stands at $263.0 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) shares fell 14.97% to $2.0. The market value of their outstanding shares is at $51.6 million. </li>
<li>QXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) stock declined by 8.02% to $16.88. The market value of their outstanding shares is at $8.7 billion. </li>
<li>Key Tronic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTCC#NASDAQ">KTCC</a>) stock declined by 7.61% to $2.89. The market value of their outstanding shares is at $31.1 million. </li>
<li>Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) stock declined by 7.41% to $3.5. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) shares fell 6.58% to $7.53. The company's market cap stands at $70.9 million. As per the news, the Q1 earnings report came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CIFR

EVLV

GREE

INUV

KEYS

KTCC

PCLA

TZUP

WOLF

12 Information Technology Stocks Moving In Tuesday's After-Market Session

Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>)&nbsp;("Garrett" or the "Company"), a leading differentiated automotive technology provider, today announced a proposed secondary public offering of 17,000,000 shares of the Company's common stock held by certain entities managed by affiliates of Oaktree Capital Management, L.P., Centerbridge Partners, L.P. and Cyrus Capital Partners, L.P. (collectively, the "Selling Stockholders"). The underwriters will have a 30-day option to purchase at their own election up to an additional 2,550,000 shares of common stock from the Selling Stockholders. The Selling Stockholders will receive all of the net proceeds from the proposed offering. The Company is not selling any shares and will not receive any proceeds from the proposed offering.
Garrett has authorized the concurrent purchase from the underwriters of approximately 2 million shares of common stock as part of the secondary public offering (the "Repurchase"), subject to the completion of the offering, subject to a maximum aggregate repurchase amount of $25 million. The Repurchase is part of the Company's existing $250 million share repurchase program. The underwriters will not receive any compensation for the shares being repurchased by the Company pursuant to the Repurchase.

Offerings

Buybacks

Garrett Motion Announces 17M Share Secondary Offering By Oaktree, Centerbridge, And Cyrus Capital And $25M Concurrent Share Repurchase Under Existing Buyback Program

Management

MTUS

Metallus Promotes Kristopher R. Westbrooks To President And COO And John M. Zaranec To CFO, Effective June 16, 2025

CXApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/05/ac45529780/cxapp-inc-nasdaq-cxai-reports-strong-q125-customer-success-metrics-and-adoption-of-agentic-ai-bas"> from the report. </a>
The Details: CXApp reported quarterly losses of eight cents per share, which beat the analyst consensus estimate of losses of 24 cents and is up from losses of 34 cents from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45524565/nvidias-1-trillion-comeback-shows-deepseek-no-longer-spooks-wall-street?utm_source=articleShare">Nvidia&#8217;s $1 Trillion Comeback Shows DeepSeek No Longer Spooks Wall Street&nbsp;</a>
For the first quarter, CXApp reported: 
<ul class="wp-block-list">
<li>ARR Expansion Growth of more than 130% and renewals for three large Fortune 500 clients</li>
<li>Subscription to One time Revenue split of 99%, up from 87% in the first quarter of 2024.</li>
<li>Gross Margin of 88%, up from 82% in the first quarter of 2024.</li>
</ul>
&#8220;The CXAI platform anchored on customer experience (CX) and artificial intelligence (AI) is the most advanced technology solution solving the biggest problems in our industry post the pandemic — the Return to Office (RTO) and Employee Engagement. The first quarter in 2025 has seen a resurgence of RTO mandates and an increased interest in Agentic AI solutions that are transformational to employee experiences,&#8221; CEO Khurram Sheikh commented.
CXAI Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, CXApp stock was down 3.60% at $1.34 after-hours on Tuesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Image: Shutterstock

Earnings

After-Hours Center

CXAI

CXApp Reports Better-Than-Expected Q1 Earnings: Details

In the current market session, Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) share price is at $349.50, after a 0.87% drop. Over the past month, the stock spiked by 20.03%, but over the past year, it actually decreased by 1.81%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1747774830_0.png" alt="Past Year Chart" />

<h3>Evaluating Caterpillar P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Caterpillar has a lower P/E than the aggregate P/E of 51.5 of the Machinery industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747774830_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Caterpillar

CSWC

Capital Southwest Corp Files For Common Stock Offering Of Up To $1B

Southwest Gas Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWX#NYSE">SWX</a>) ("Southwest Gas Holdings" or the "Company") today announced the commencement of an underwritten secondary public offering of Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) ("Centuri") common stock (the "Offering"), pursuant to which Southwest Gas Holdings, as the selling stockholder, is offering 9,000,000 existing shares of Centuri's common stock. Southwest Gas Holdings expects to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of Centuri's common stock.
In addition to the shares of Centuri's common stock sold in the Offering, Southwest Gas Holdings announced that Icahn Partners and Icahn Partners Master Fund LP, investment entities affiliated with&nbsp;Carl C. Icahn, will purchase an aggregate of&nbsp;$50 million in shares of&nbsp;Centuri's common stock from Southwest Gas Holdings in a concurrent private placement at a price per share equal to the Offering price per share. The concurrent private placement is expected to close immediately following the closing of the Offering and is subject to the satisfaction or waiver of customary closing conditions, including the completion of the Offering. The sale of these shares will not be registered under the Securities Act of 1933, as amended (the "Securities Act"). The closing of the Offering is not conditioned upon the closing of the concurrent private placement.

Southwest Gas Holdings Launches Secondary Public Offering Of 9M Centuri Shares And Announces $50M Private Placement With Icahn Affiliates At Offering Price

WIIM

D.R. Horton shares are trading higher in possible sympathy with Toll Brothers, which rose after reporting Q2 results.

I got into the investment business on a steady diet of Graham and Whitman. But that was the 1980s and early 1990s – the golden age of dealmakers and junk bonds, leveraged buyouts and greenmail. 
Long before the players became gentlemanly private equity titans and activist investors, they were raiders, vultures, and even, in one famous book about the RJR deal, barbarians.
Legendary fortunes were made, reputations created and shattered.
All of these high-return, high-flying strategies shared a common thread. Leveraged buyouts, distressed investing and risk arb were all just variations on the value investing theme.
The private equity giants of today are still doing this. Thanks to their quarterly filings, you can copy their investment approach—a strategy that has beaten the markets 4-to-1 since 2001.
Even the creation of the junk bond market was based on Michael Milken&#8217;s studies on the returns from buying undervalued lower-rated bonds, a strategy founded on basic value investing principles.
The big winners in all these strategies took value investing and added debt.
It was like adding nitro to the tank of a stock car. If you could control the vehicle at high speed through the corners, there was no race you couldn&#8217;t win.
Although the golden age of risk arb and the smaller investors&#8217; ability to compete in distressed debt are all behind us, we can still use the combination of debt and value investing to beat the index by a wide margin.
When the 13F filings come out every quarter, most of the short-attention-spans in the market today head for the same filings at the same time.
Warren, Cathie, Stanley, Tepper and Seth still get all the attention.
I may get around to those at some point, but one of the first places I turn is to the leading private equity firms.
Firms like Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) and KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) still use basic principles of value investing along with a healthy dose of debt to drive massive returns for themselves and their investors.
What most people do not realize is that these firms also have large public securities portfolios, and stealing their ideas has created some massive market-beating opportunities.
If you had bought shares of Mr. Cooper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) when it first appeared in KKR&#8217;s public portfolio in 2018, you could have made almost ten times your money.
Buying shares of AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) when KKR first revealed its position would have resulted in gains of almost seven times your initial cost.
DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) would have delivered gains of 3x in just a few years.
Owning the firm&#8217;s top ten holdings since 2001 would have beaten the market by a 4-to-1 margin.
I do not care what the media darling investors bought last quarter. Tell me what the profit pirates at KKR own, and I can create an opportunity to score massive gains.
The current top ten holdings for KKR are:
BrightSpring Health Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) provides home and community-based health services to complex patients, positioning itself in a niche with long-term demographic tailwinds. The company is newly public and pursuing scale through both organic growth and targeted acquisitions in behavioral and specialty pharmacy segments.
Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) is a global distributor of dental and medical supplies primarily serving small- and mid-sized practices. The company generates stable cash flow and has a long history of disciplined capital deployment, though growth is modest and sensitive to procedure volume trends.
BrightView (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) is the largest commercial landscaping services provider in the U.S., with recurring maintenance revenue making up the majority of its business. Under new leadership, the firm is undergoing a restructuring push to improve margins and reduce debt after years of underperformance.
KKR Real Estate Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is a commercial mortgage REIT focused on senior loans backed by institutional-grade real estate, primarily in urban markets. It offers a high dividend yield but remains exposed to office market weakness and refinancing risk in a higher-rate environment.
Madison Square Garden Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>) owns marquee sports franchises, including the New York Knicks and Rangers, offering investors a rare asset-backed play on professional sports. Valuation is driven more by franchise appreciation than earnings power, making it a long-duration, event-driven asset.
Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) is a leading cruise operator with a strong focus on premium and upscale offerings across its brand portfolio. The company is rebounding from pandemic-era disruptions, though it still carries significant leverage and remains sensitive to fuel and labor costs.
Bausch Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) is a diversified specialty pharmaceutical company with exposure to eye health, dermatology, and branded generics. However, the company is still burdened by high legacy debt. While it&#8217;s pursuing a turnaround strategy and asset divestitures, legal overhangs and weak cash flow remain headwinds.
FS KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) is one of the largest business development companies, focused on senior secured lending to middle-market companies with an emphasis on downside protection. It offers a double-digit yield and strong sponsor backing, though credit quality and NAV stability require close monitoring.
Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSGY#NYSE">CSGY</a>) is a cash-generating E&amp;P company with a private equity-backed structure and a focus on acquiring and optimizing mature, low-decline assets. The firm maintains a disciplined capital return framework and hedging strategy, making it a defensive upstream play with yield upside.
BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) is a commercial-stage biopharmaceutical company developing treatments for genetic diseases and cancers with clear genetic drivers. Its lead drug, Attruby (acoramidis), approved in late 2024 for transthyretin amyloid cardiomyopathy, significantly outperformed sales expectations in its first full quarter, positioning the company as a strong competitor in the cardiomyopathy treatment market.
<h2 class="wp-block-heading">Turn Market Mayhem Into Profit Signals This Memorial Day</h2>
Get real-time portfolio alerts, daily stock ideas, and a suite of pro-grade tools — all in one elite membership. For a limited time, you can access Benzinga Edge at 60% off. Secure Your 60% Memorial Day Discount <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-memorial-day-special/?utm_campaign=mdw-sale&amp;utm_adType=sponsorad&amp;utm_ad=RD052025/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">HERE</a>.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

BBIO

BTSG

COOP

CSGY

DASH

HSIC

KREF

MSGS

NCLH

The Smart Money Is Buying These 10 Stocks

Keysight Technologies shares are trading higher following better-than-expected Q2 financial results.

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) has outperformed the market over the past 15 years by 6.02% on an annualized basis producing an average annual return of 18.1%. Currently, TJX Companies has a market capitalization of $151.36 billion. 
Buying $100 In TJX: If an investor had bought $100 of TJX stock 15 years ago, it would be worth $1,190.12 today based on a price of $134.64 for TJX at the time of writing.
<h3>TJX Companies's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747773927_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In TJX Companies 15 Years Ago Would Be Worth This Much Today

DaVita Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) ("DaVita") announced today the upsize and pricing of its previously announced private offering (the "offering") of its 6.750% senior notes due 2033 (the "2033 notes"). The aggregate principal amount of the 2033 notes offered in the offering was increased from $750 million to $1 billion, and the 2033 notes were priced at 100.000% of their face amount to yield a 6.750% coupon. The offering is expected to close on May 23, 2025, subject to satisfaction of customary closing conditions.

DaVita Announces Upsize And Pricing Of Its Previously Announced Private Offering Of Its 6.750% Senior Notes Due 2033 From $750M To $1B

Earnings Misses

EARN

Ellington Credit Q1 Adj. EPS $0.26 Misses $0.27 Estimate, Sales $9.25M Miss $9.35M Estimate

<h2 class="wp-block-heading">The request to get serious</h2>
Let's talk about exclusivity in M&amp;A transactions. The request for exclusivity often occurs at that moment in a deal where a buyer approaches a seller with the intention of making a commitment. "Hey, we want to buy you, but before we go too far down this road, we need to make sure you're not talking to anyone else." It's the financial equivalent of locking down a relationship: no swiping left or right while we're trying to make this work, okay?
Of course, in finance, nothing is ever that simple.
<h2 class="wp-block-heading">The exclusivity agreement</h2>
Let's say you're a company looking to get acquired, and you've been approached by a suitor. Maybe several, if you're lucky. Before the mayhem of the bidding war ensues, the buyer you like says, "We want a deal, but we need exclusivity for 45 days." Shorthand for, "We don't want you talking to anyone else while we're hammering out the details." Fair enough, right?
Here's the buyer's logic: Deals require lots of upfront investment in time and resources for due diligence, analysis on deal structuring etc. Buyers don't want to spend millions just to find out halfway through that you've been secretly talking to someone else and now you're going to pursue Option B instead.
<h2 class="wp-block-heading">Exclusivity's little twist: Is it really exclusive?</h2>
An exclusivity agreement sounds like it would be ironclad &#8211; no talking to other buyers, no shopping yourself around, nothing. You're locked in, right? Not quite. It's more like a promise that you won't actively seek out other deals. The door isn't totally locked – it's just slightly ajar. &nbsp;The company selling itself might still get unsolicited offers. If someone wants to slide a very tempting note under the door, technically no one is stopping them.
<h2 class="wp-block-heading">So, what happens when someone else knocks on your door?</h2>
What if, during your 45-day exclusivity window, another buyer shows up and waves a better deal in front of you? Now you're in a tough spot. Do you go back to your exclusive partner and say, "We've been offered something better. What can you do?"
You may be subject to a "no-shop" clause (i.e, you can't actively seek other offers), but you still need to protect yourself if an unsolicited offer presents a better opportunity. Ultimately, a seller's Board has a fiduciary duty to maximize value for its shareholders and must be cautious not to waive this obligation due to an exclusivity arrangement.
In other words, you can't shop yourself around, but if another buyer approaches you, well… your phone isn't exactly on airplane mode.
<h2 class="wp-block-heading">What if it all falls apart?</h2>
Let's say you've been in an exclusive process, hammering out details, and then the exclusivity period ends without a deal.&nbsp; This happened during Paramount's initial discussions with Skydance in mid-2024. Now, you're free to talk to other suitors like Paramount did with Apollo and Sony, yet there's no guarantee you'll get a better offer. Meanwhile, Skydance is still technically around (and may ultimately get to a signed deal), but the door is open for interlopers to engage in discussions.
The end of the exclusivity period gives you options, yet it also creates uncertainty. On the one hand, you can explore other opportunities, but on the other, new buyers may wonder why the last party didn't commit.
<h2 class="wp-block-heading">So, is exclusivity worth it?</h2>
It depends.
Here's where it gets tricky: exclusivity periods have been getting longer in recent years. In 2021, only 6% of deals had exclusivity periods longer than 60 days, but by 2022, that number increased to nearly 40%, a trend that is expected to continue (<a href="https://www.goodwinlaw.com/en/insights/publications/2023/05/insights-privateequity-ma-durations-exclusivity-periods?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">Goodwin, 2023</a>).
So, while buyers prefer long exclusivity periods to facilitate comprehensive due diligence, sellers might be locking themselves into a deal that could ultimately fall apart. If exclusivity doesn&#8217;t result in a deal, a seller could spend months watching potential bidders fade away.
Exclusivity is often worth considering if:
<ol class="wp-block-list">
<li>The seller has a strong pre-existing relationship with a buyer</li>
<li>A buyer presents an exceptionally attractive offer (assuming they're serious)</li>
<li>The seller is in financial distress and exclusivity will facilitate a more rapid diligence timeline</li>
</ol>
Ultimately, agreeing to exclusivity with a buyer can be a double-edged sword. These decisions should always be made case-by-case, in consultation with financial advisors who can help evaluate the unique dynamics of each transaction.

Locked In: How Exclusivity Shapes the M&A Landscape

Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) released its second-quarter results after Tuesday's closing bell. Here's a look at the<a href="https://www.benzinga.com/pressreleases/25/05/b45529263/keysight-technologies-reports-second-quarter-2025-results"> details from the report. </a>
The Details: Keysight Technologies reported quarterly earnings of $1.70 per share, which beat the consensus estimate of $1.65. Quarterly revenue came in at $1.31 billion, which beat the Street estimate of $1.28 billion and is up from revenue of $1.22 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45524565/nvidias-1-trillion-comeback-shows-deepseek-no-longer-spooks-wall-street?utm_source=articleShare">Nvidia&#8217;s $1 Trillion Comeback Shows DeepSeek No Longer Spooks Wall Street&nbsp;</a>
<ul class="wp-block-list">
<li>Communications Solutions Group reported revenue of $913 million in the second quarter, up 9% from the prior year, reflecting 9% growth in commercial communications and 9% growth in aerospace, defense and government.</li>
<li>Electronic Industrial Solutions Group reported revenue of $393 million in the second quarter, up 5% from the prior year, reflecting growth in semiconductor and general electronics, partially offset by a decline in automotive and energy.</li>
</ul>
&#8220;Keysight delivered strong second quarter results with revenue and earnings per share above the high end of guidance. This quarter&#8217;s performance underscores the strength of our long-term strategy, deep customer engagement and disciplined execution,&#8221; said Satish Dhanasekaran, Keysight CEO.
&#8220;Even as we are monitoring the overall macroeconomic environment, we continue to see a healthy funnel of opportunities and are raising full-year growth expectations to the midpoint of our long-term 5%-7% target,&#8221; Dhanasekaran added.
Outlook:&nbsp;Keysight sees third-quarter EPS is a range of $1.63 to $1.69, versus the $1.69&nbsp;analyst estimate, and revenue of between $1.305 billion and $1.325 billion, versus the&nbsp;$1.3 billion&nbsp;estimate.
KEYS Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Keysight stock was up 4.60% at $170.28 after-hours Tuesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Image: Shutterstock

Keysight Technologies Stock Climbs After Q2 Results: Here's Why

XWELL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) reported quarterly losses of $(1.00) per share. This is a 66.67 percent decrease over losses of $(0.60) per share from the same period last year. The company reported $7.02 million in sales this quarter. This is a 19.52 percent decrease over sales of $8.73 million the same period last year.

XWELL Q1 EPS $(1.00) Down From $(0.60) YoY, Sales $7.02M Down From $8.73M YoY

President Donald Trump has touted multi-trillion-dollar investment commitments as proof that his economic strategy is delivering a historic revival of <a href="https://www.benzinga.com/topic/donald-trump">American manufacturing and infrastructure. </a>
Yet, behind the massive figures, new analysis from Goldman Sachs suggests the actual economic impact could be far more modest.
Foreign governments and corporations have pledged over $6 trillion in U.S. investments, including $2 trillion from companies and $4.2 trillion from foreign governments, according to Goldman Sachs economist Joseph Briggs.
Just a week ago, President Trump secured $2 trillion in investment commitments from Gulf nations, including Saudi Arabia, Qatar and the United Arab Emirates. Meanwhile, Japan pledged $1 trillion.
Among the companies making the largest pledges, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) announced $787 billion, followed by International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with $409 billion, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with $302 billion, and Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with $35 billion.
"We expect the impact on U.S. investment to be smaller than suggested by these promises for three reasons," Briggs said in a report, highlighting project uncertainty, limited alignment with national accounts definitions, and overlap with prior plans.
<h3 class="wp-block-heading">The Real Investment Boost May Be Just $30B–$135B</h3>
After analyzing the announcements and stripping out less tangible commitments—like purchases of goods, partnerships, and reannounced projects—Goldman estimates that only $135 billion in new annual investment is directly tied to GDP-relevant projects like physical capital expenditures and R&amp;D. 
Applying historical realization rates and analyst feedback, the bank sees the likely net impact closer to $30 billion per year, or just 0.1% of U.S. GDP.
That figure starkly contrasts with headline projections that initially suggested a 4% GDP boost over time.
<h3 class="wp-block-heading">Why The Gap?</h3>
Many large-cap companies, including Apple Inc. and Nvidia Corp., have promised massive investments—$500 billion each over multiple years—but their past spending doesn't align. 
Apple spent just $10 billion on U.S. capex and $31.4 billion on global R&amp;D in 2024. Nvidia's corresponding figures were even lower, suggesting that headline figures may include spending on acquisitions, partnerships or input costs that don't translate into actual U.S. capital formation.
Further, Goldman's equity analysts found that 69% of the corporate investments likely overlap with previously planned spending, with just 6% seen as mostly new.
Goldman Sachs noted that &#8220;these announcements have not driven major upgrades to equity analyst capex forecasts.&#8221;
<h3 class="wp-block-heading">Foreign Deals May Help, If They Materialize</h3>
&#8220;In contrast to company-level announcements, investment promises from the United Arab Emirates, Saudi Arabia, Qatar, and Japan could provide a material incremental increase if they materialize,&#8221; Briggs said.
Countries like Saudi Arabia, Qatar, Japan and the UAE have announced ambitious commitments—from AI data centers to energy infrastructure and defense purchases.
Both Saudi Arabia and Qatar emphasized large-scale purchases of U.S. goods—$142 billion in defense contracts from Saudi Arabia and $96 billion in aircraft orders from Qatar—which would support U.S. GDP through exports, but not count as domestic investment. 
Yet, the lack of specificity on most other announced projects suggests that much of the foreign capital may contribute indirectly by lowering financing costs rather than driving immediate, measurable increases in U.S. capital formation.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45528339/us-assets-still-vital-in-global-portfolios-despite-debt-downgrade-blackrock">US Assets Still Vital In Global Portfolios Despite Debt Downgrade: BlackRock </a></li>
</ul>
Photo: Shutterstock

Analyst Color

Large Cap

Politics

Econ #s

Analyst Ratings

AAPL

NVDA

Trump's $6 Trillion Investment Deals Face Reality Check: Only A Fraction May Reach The Real Economy

Press Releases

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Personalis to Announce First Quarter 2025 Financial Results

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Personalis Reports First Quarter 2025 Financial Results

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Personalis

Personalis (PSNL) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌